{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:32Z","timestamp":1793766452138,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102617","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:34:34Z","timestamp":1783380874000},"page":"102617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-3011","authenticated-orcid":false,"given":"Akimasa","family":"Sanagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102617_bib0001","unstructured":"National Institutes of Health \u2013 National Cancer Institute Surveillance, Epidemiology and end results program. Cancer stat facts S: bladder cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html Accessed: August 29, 2025."},{"key":"10.1016\/j.clgc.2026.102617_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19524","article-title":"Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates","volume":"8","author":"Lian","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102617_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102617_bib0004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102617_bib0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102617_bib0006","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2026.102617_bib0007","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0008","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0009","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.0250","article-title":"Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"8","author":"Yajima","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102617_bib0011","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0012","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102617_bib0013","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102617_bib0014","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1093\/oncolo\/oyac170","article-title":"Regarding \u201cmanagement of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin\u201d","volume":"27","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102617_bib0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102617_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/iju.15640","article-title":"Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: a landmark analysis","volume":"32","author":"Taguchi","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102617_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2026.102617_bib0018","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2026.102617_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2026.102617_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.clgc.2026.102617_bib0022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.clgc.2026.102617_bib0023","unstructured":"The guidelines of preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. Available at: https:\/\/www.prisma-statement.org\/ Accessed: August 3, 2025."},{"key":"10.1016\/j.clgc.2026.102617_bib0024","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2026.102617_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.14376","article-title":"Addressing immortal time bias in precision medicine: practical guidance and methods development","volume":"60","author":"Weymann","year":"2025","journal-title":"Health Serv Res"},{"key":"10.1016\/j.clgc.2026.102617_bib0026","unstructured":"Wells G.A., Shea B., O\u2019Connell D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp Accessed: August 20, 2025."},{"key":"10.1016\/j.clgc.2026.102617_bib0027","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102617_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin\u2013related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152648","volume":"16","author":"Nakane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102617_bib0030","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.21873\/anticanres.17115","article-title":"Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: the UROKYU study","volume":"44","author":"Furubayashi","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2026.102617_bib0031","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0032","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0033","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/iju.70030","article-title":"Impact of skin adverse events on prognosis in patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin: a real-world multicenter study","volume":"32","author":"Ozaki","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102617_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115427","article-title":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin","volume":"222","author":"Belka\u00efd","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2026.102617_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE study","volume":"14","author":"Nizam","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2026.102617_bib0036","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10147-024-02672-3","article-title":"Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response","volume":"30","author":"Nagayama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0037","article-title":"Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan","volume":"7","author":"Kita","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab vedotin for metastatic urothelial carcinoma: comprehensive treatment outcomes and prognostic insights from a multicenter real-world study (YUSHIMA study)","volume":"23","author":"Nakamura","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102617_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70329","article-title":"Clinical features and risk factors of enfortumab vedotin-induced peripheral neuropathy in patients with metastatic urothelial carcinoma: a multicenter retrospective study (YUSHIMA study)","volume":"33","author":"Soma","year":"2026","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2026.102617_bib0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euros.2022.11.003","article-title":"Surrogate endpoints as predictors of overall survival in metastatic urothelial cancer: a trial-level analysis","volume":"47","author":"Ghali","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102617_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105843","article-title":"Meta-analysis of surrogate endpoints for overall survival in extensive-stage small-cell lung cancer","volume":"10","author":"Durer","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2026.102617_bib0042","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/cpt.3627","article-title":"Characterizing treatment effect heterogeneity using real-world data","volume":"117","author":"Thelen","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clgc.2026.102617_bib0043","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","article-title":"The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example","volume":"31","author":"Duchesneau","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clgc.2026.102617_bib0044","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102617_bib0045","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/cncr.34244","article-title":"Guarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity","volume":"128","author":"Cheung","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102617_bib0046","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/cncr.34242","article-title":"Reply to \u201cGuarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity\u201d","volume":"128","author":"Foster","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102617_bib0047","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/eb-2014-102035","article-title":"Accounting for baseline differences in meta-analysis","volume":"18","author":"Chaimani","year":"2014","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.clgc.2026.102617_bib0048","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jjco\/hyad172","article-title":"Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review","volume":"54","author":"Taguchi","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0049","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10147-025-02709-1","article-title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102617_bib0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjd.21022","article-title":"Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin","volume":"187","author":"Penny","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clgc.2026.102617_bib0051","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.70258","article-title":"Clinicopathologic and immunohistochemical features of enfortumab vedotin-induced cutaneous toxicity","author":"Repetto","year":"2026","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clgc.2026.102617_bib0052","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21873\/invivo.13843","article-title":"Impact of relative dose intensity of enfortumab vedotin for advanced urothelial carcinoma","volume":"39","author":"Furubayashi","year":"2025","journal-title":"In Vivo"},{"key":"10.1016\/j.clgc.2026.102617_bib0053","article-title":"Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma","author":"Lee","year":"2026","journal-title":"medRxiv [Preprint]"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:26Z","timestamp":1793765786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001175"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102617","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Enfortumab Vedotin-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102617"}}